Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Virus diversity and escape from immune responses are the biggest challenges to the development of an effective vaccine against HIV-1. We hypothesized that T-cell vaccines targeting the most conserved regions of the HIV-1 proteome, which are common to most variants and bear fitness costs when mutated, will generate effectors that efficiently recognize and kill virus-infected cells early enough after transmission to potentially impact on HIV-1 replication and will do so more efficiently than whole protein-based T-cell vaccines. Here, we describe the first-ever administration of conserved immunogen vaccines vectored using prime-boost regimens of DNA, simian adenovirus and modified vaccinia virus Ankara to uninfected UK volunteers. The vaccine induced high levels of effector T cells that recognized virus-infected autologous CD4(+) cells and inhibited HIV-1 replication by up to 5.79 log10. The virus inhibition was mediated by both Gag- and Pol- specific effector CD8(+) T cells targeting epitopes that are typically subdominant in natural infection. These results provide proof of concept for using a vaccine to target T cells at conserved epitopes, showing that these T cells can control HIV-1 replication in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034 · cited 1×
“In contrast to the STEP study, the RV144 trial, which tested a combination of ALVAC-vectored Env prime and Env protein boost, gave 31% protection against acquisition, most likely through the generation of non-neutralizing anti-Env antibodies [38, 39].”
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“This is a very important step forward, moving from promising preclinical observations in animals to detailed studies in humans, given that immune responses in experimental animals do not always predict how humans will respond [32, 33, 34].”
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808 · cited 2×
“In contrast to the STEP study, the RV144 trial, which tested a combination of ALVAC-vectored Env prime and Env protein boost, gave 31% protection against acquisition, most likely through the generation of non-neutralizing anti-Env antibodies [38, 39].”
Self-citationBuchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713 · cited 2×
“…505 trials, which all used HAdV-5 as a vector and showed trends of increased acquisition of HIV-1 in vaccine recipients, there is some concern that all adenoviruses may be precluded from use as prophylactic HIV-1 vaccines [32, 46], although more qualified recommendations might be appropriate [47].”
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load
Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1520 · Cited by 1,032 · cited 3×
“Because protective CD8 + T-cell responses in infected patients are mostly specific for Gag [10, 11, 12], while Pol-specific responses are less common [31], we determined whether vaccine induced Pol-specific T cells were as effective in the VIA as those specific for Gag.”
HIV evolution: CTL escape mutation and reversion after transmission
Leslie, A. J., Pfafferott, K. J., Chetty, P., Draenert, R., Addo, M. M., Feeney, M., Tang, Y., Holmes, E. C., Allen, T., Prado, J. G., et al. (2004) · Nature Medicine · doi:10.1038/nm992 · Cited by 847 · cited 1×
“It is known that escape mutations in many of these conserved regions will reduce the HIV-1 fitness [18, 19, 20, 21].”
BackgroundDiversity Considerations in HIV-1 Vaccine Selection
Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H., Bhattacharya, T., et al. (2002) · Science · doi:10.1126/science.1070441 · Cited by 811 · cited 2×
“Vaccine-induced T cells and antibodies face the same two problems: trying to match the enormous variability of the infecting HIV-1 and its subsequent ability to escape immune control by mutation [7].”
Goonetilleke, N., Liu, M. K. P., Salazar-Gonzalez, J. F., Ferrari, G., Giorgi, E., Ganusov, V. V., Keele, B. F., Learn, G. H., Turnbull, E. L., Salazar, M. G., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090365 · Cited by 641 · cited 1×
“Given the HIVconsv epitope subdominance in natural infection, this broadly concurs with a detailed mapping of CD8 + T-cell responses during acute HIV-1 infection, which identified about 30% of previously undescribed epitopes, some of which were in variable regions and escaped early [44].”
Self-citationSáez-Cirión, A., Lacabaratz, C., Lambotte, O., Versmisse, P., Urrutia, A., Boufassa, F., Barré-Sinoussi, F., Delfraissy, J.-F., Sinet, M., Pancino, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611244104 · Cited by 616 · cited 1×
“However, inhibition of HIV-1 replication in activated CD4 + T cells by autologous CD8 + T cells in vitro does correlate well with virus control in vivo [3, 4, 5, 6].”
Kelleher, A. D., Long, C., Holmes, E. C., Allen, R. L., Wilson, J., Conlon, C., Workman, C., Shaunak, S., Olson, K., Goulder, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.3.375 · Cited by 448 · cited 1×
“It is known that escape mutations in many of these conserved regions will reduce the HIV-1 fitness [18, 19, 20, 21].”
Self-citation
Cited by
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348
Self-citationMoyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
“epitopes irrelevant for HIV-1 generated by two juxtaposed regions.(20) (B) Vaccines used in this work.”
MethodSelf-citation5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
Cappuccini, F., Pollock, E., Stribbling, S., Hill, A. V. S., & Redchenko, I. (2017) · Oncotarget · doi:10.18632/oncotarget.17666 · Cited by 31
Self-citation
Metadata
- Authors
- Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E.-J., Black, A., Bridgeman, A., Rosario, M., Hill, A. V., Berrie, E., Moyle, S., Frahm, N., Cox, J., Colloca, S., Nicosia, A., Gilmour, J., McMichael, A. J., Dorrell, L., & Hanke, T.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 22
- Issue
- 2
- Pages
- 464-475
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1991737813
- Cited by
- 199
- References
- 46
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.